menu
    • menu
    [{"orgOrder":0,"company":"Eleva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Factor H","moa":"CFH","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Eleva","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eleva \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eleva \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eleva

                            Germany arrow
                            ESCRS
                            Not Confirmed

                            Eleva

                            Germany arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Factor H

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eleva Doses Factor H Therapy In C3-Glomerulopathy To Healthy Volunteers

                            Details : The lead program, Factor H (CPV-104), a recombinant human complement Factor H, has entered a Phase 1/2 clinical studies to treat C3 Glomerulopathy (C3G).

                            Product Name : CPV-104

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 07, 2024

                            Lead Product(s) : Factor H

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth